The first patient is a 69-year-old woman with left breast invasive carcinoma (ER+, PR+, HER2-), status post bilateral mastectomy, adjuvant chest and axillary radiation, and aromatase inhibitor therapy, with two PIK3CA gain of function mutations. This evidence concerns the gene ERBB2 and invasive breast carcinoma.